Approximately 10–15% couples in Europe face infertility, and in a significant number of cases, it is linked to male reproductive health disorders. In this context, researchers at Riga Stradins University, within the “BioPhoT” platform, are developing a new diagnostic solution called “SPERMFREE,” which offers a more precise approach to assessing severe male infertility.
Within the “BioPhoT” program, an RSU research team is developing a diagnostic method called “SPERMFREE.” This method offers a non-invasive approach to assessing severe male infertility. It is based on the analysis of extracellular DNA in ejaculate and allows for the determination of whether sperm production is occurring in the body *before* any potential surgical intervention. This approach enables doctors to make more precise and data-driven decisions regarding further treatment strategies.
A segment on Latvian Television's “Rīta panorāma” emphasized that currently available diagnostic methods do not always allow for the prediction of invasive procedure outcomes, which can mean a physically and emotionally arduous experience for patients. The new solution has the potential to reduce the number of unnecessary surgeries while making the diagnostic process faster and more patient-friendly.
This project is an example of how research developed in Latvia is moving closer to practical application in healthcare, creating solutions with a clear impact on patients' quality of life and the efficiency of the health system.
Invitation to watch plot!
